Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons with Commercial Insurance and Likely Injection Drug Use

Estimating abysmally low rates of PrEP prescribing in administrative claims data

By Jake R. Morgan, PhD October 3, 2022
Jake R. Morgan, PhD, CHERISH investigator and Research Assistant Professor at Boston University School of Public Health.

The United States has made important strides to reduce the incidence and negative outcomes of HIV, including increasing the availability of effective treatment and prevention in the form of pre-exposure prophylaxis (PrEP).

We need better ways of identifying those who would benefit from PrEP in claims data, but even an imperfect approach shows striking gaps.

Jake R. Morgan, PhD